ESPE Abstracts

ESPE Abstracts

Published by BioScientifica
Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE (ESPE 2018)

Athens, Greece
27 Sept 2018 - 29 Sept 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Poster Presentations

GH & IGFs P3

Previous section
GH & IGFs P2
Table of contents
Next section
Growth & Syndromes P1

hrp0089p3-p192 | GH & IGFs P3

Good Growth Response to Growth Hormone Therapy in Short Children with Normal Growth Hormone Secretion

hrp0089p3-p193 | GH & IGFs P3

Growth Hormone Deficiency Intwo Children with Williams-Beuren Syndrome: The Long-Term Response to Growth Hormone (GH) Therapy

hrp0089p3-p194 | GH & IGFs P3

Growth Hormone Treatment: Does Timing Matter?

hrp0089p3-p195 | GH & IGFs P3

Support for Patients Treated with Growth Hormone to Reach their Growth Potential: Addressing Adherence Barriers through Personalised Behavioural Patient-support Programmes

hrp0089p3-p196 | GH & IGFs P3

Main Discrepancies between Predicted and Observed Growth Responses with iGRO in Children Treated with GHr in Spain

hrp0089p3-p197 | GH & IGFs P3

Adherence and Long-term Outcomes of Therapy in Pediatric Subjects in Greece Using Easypod™ Electromechanical Device for Growth Hormone Treatment: The Phase IV Multicentre Easypod™ Connect Observational Study (ECOS)

hrp0089p3-p198 | GH & IGFs P3

Growth Hormone Deficiency in Neurofibromatosis: Report of Four Cases

hrp0089p3-p199 | GH & IGFs P3

Extremely Low Body Mass Index Negatively Impact the Response to Growth Hormone Treatment in Children with Growth Hormone Deficiency

hrp0089p3-p200 | GH & IGFs P3

Small for Gestational Age (SGA) Patients with Premature Treatment Discontinuation: Their Journey in French Real-life Settings

hrp0089p3-p201 | GH & IGFs P3

Effects on Near-adult Height and Safety of Recombinant Human Growth Hormone in Growth Hormone Deficiency and Turner Syndrome Patients: Results from the LG Growth Study

hrp0089p3-p202 | GH & IGFs P3

Final Adult Height After Growth Hormone Treatment in Patients with Turner Syndrome

hrp0089p3-p203 | GH & IGFs P3

Results of Mecasermin Treatment in Pediatric Patients Evaluated for Severe and Partial Primary Deficiency of IGF-1

hrp0089p3-p204 | GH & IGFs P3

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

hrp0089p3-p205 | GH & IGFs P3

Small for Gestational Age (SGA) Patients in Real Life French Clinical Practice: What is the Difference Between Good and Poor Responders to GH Treatment

hrp0089p3-p206 | GH & IGFs P3

Body Mass Index (BMI) in Patients with Growth Hormone Deficiency (GHD) at Diagnosis, One Year and Two Years After Treatment with Growth Hormone (GH)

hrp0089p3-p207 | GH & IGFs P3

Erythropoietin and Granulocyte Macrophage Colony Stimulating Factor Levels in Growth Hormone Deficient Children after 1 Year of Growth Hormone Therapy

hrp0089p3-p208 | GH & IGFs P3

Cost-effectiveness of Growth Hormone Therapy in Children in Russia

hrp0089p3-p209 | GH & IGFs P3

Vitamin D Status in Children with Isolated Idiopathic GH Deficiency (GHD) in North and Central Greece

hrp0089p3-p210 | GH & IGFs P3

A Pilot Study for Comparing Efficacy and Safety of the CinnaTropin® to the Reference Recombinant Human GH in Children with Isolated GH Deficiency and Multiple Pituitary Hormone Deficiency

hrp0089p3-p211 | GH & IGFs P3

Study of the Effectiveness of GH in Children Born Small for Gestational Age in an Area of Northwestern Spain and its Associated Factors

hrp0089p3-p212 | GH & IGFs P3

Height Velocity and Height Gain in the First Year of GH Treatment: Predictive Factors of Good Statural Response in Small for Gestational Age (SGA) Patients

hrp0089p3-p213 | GH & IGFs P3

Role of Insulin like Growth Factors on the Growth Parameters in Children with Acquired Hypothyroidism: An Analysis

hrp0089p3-p214 | GH & IGFs P3

Two Siblings with Short Stature

hrp0089p3-p215 | GH & IGFs P3

RHGH Replacement Therapy and Side-Effects: A Retrospective Study of 10 Years

hrp0089p3-p216 | GH & IGFs P3

Efficacy and Safety of Recombinant Human GH in Treating Chinese Children with Idiopathic Short Stature

hrp0089p3-p217 | GH & IGFs P3

Comparison the Recombinant Human GH (rhGH) Treatment in Children with Idiopathic Short Stature (ISS) and GH Deficiency (GHD)

hrp0089p3-p218 | GH & IGFs P3

Bone Age Maturation During the Three Years of GH Treatment in Patients with Idiopathic GH Deficiency and Idiopathic Short Stature: Analysis of Data from LG Growth Study

hrp0089p3-p398 | GH & IGFs P3

Recombinant Growth Hormone Therapy in Prepubertal Children with Idiopathic Short Stature in Korea: A Phase III Randomized Trial

Published by BioScientifica

ESPE Abstracts

© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more